Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study

被引:1
|
作者
Hyun, Hakjun [1 ]
Choi, Min Joo [4 ,7 ]
Heo, Jung Yeon [5 ]
Seo, Yu Bin [6 ]
Nham, Eliel [1 ]
Yoon, Jin Gu [1 ]
Seong, Hye [1 ]
Noh, Ji Yun [1 ,2 ,3 ]
Cheong, Hee Jin [1 ]
Kim, Woo Joo [1 ,2 ,3 ]
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young [1 ,2 ,3 ]
机构
[1] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea
[2] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea
[3] Vaccine Innovat Ctr KU Med VIC K, Seoul, South Korea
[4] Catholic Kwandong Univ, Dept Internal Med, Int St Marys Hosp, Coll Med, Incheon, South Korea
[5] Ajou Univ, Dept Infect Dis, Sch Med, Suwon, South Korea
[6] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea
[7] Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res, Cheongju, South Korea
关键词
SARS-CoV-2; COVID-19; Vaccines; Adenovirus Vector; Humoral Immunity; Cellular Immunity; Adverse Events;
D O I
10.3346/jkms.2022.37.e210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. Method: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-. enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. Results: Fifty participants aged >= 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 +/- 3.0 U/mL at 3-4 weeks, 55.7 +/- 2.4 U/mL at 5-8 weeks, and 81.3 +/- 2.5 U/mL at 10-12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS- CoV-2 were 164.6 +/- 4.6 at 3-4 weeks, 313.9 +/- 3.6 at 5-8 weeks, and 124.4 +/- 2.6 at 10-12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0-29.2) at baseline, 60.0 (23.3-178.3) at 5-8 weeks, and 35.0 (13.3-71.7) at 10-12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1-2, and resolved within two days. Conclusion: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination
    Ivanko, I.
    Celap, I.
    Margetic, S.
    Marijancevic, D.
    Josipovic, J.
    Gacina, P.
    THROMBOSIS RESEARCH, 2023, 228 : 137 - 144
  • [32] Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination
    Curcio, Rosa
    Gandolfo, Vito
    Alcidi, Riccardo
    Giacomino, Luciano
    Campanella, Tommaso
    Casarola, Genni
    Rossi, Rachele
    Chiatti, Lorenzo
    D'Abbondanza, Marco
    Commissari, Rita
    Gresele, Paolo
    Pucci, Giacomo
    Vaudo, Gaetano
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : 154 - 156
  • [33] Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
    Kohmer, Niko
    Stein, Shivana
    Schenk, Barbara
    Grikscheit, Katharina
    Metzler, Melinda
    Rabenau, Holger F.
    Widera, Marek
    Herrmann, Eva
    Wicker, Sabine
    Ciesek, Sandra
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 128 : 166 - 175
  • [34] Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S)
    Troeltzsch, Matthias
    Gogl, Markus
    Berndt, Ronald
    Troeltzsch, Markus
    ORAL DISEASES, 2022, 28 : 2595 - 2596
  • [35] Acute-onset chronic inflammatory demyelinating polyneuropathy complicating SARS-CoV-2 infection and Ad26.COV2.S vaccination: report of two cases
    Fotiadou, Aggeliki
    Tsiptsios, Dimitrios
    Karatzetzou, Stella
    Kitmeridou, Sofia
    Iliopoulos, Ioannis
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2022, 58 (01)
  • [36] Acute-onset chronic inflammatory demyelinating polyneuropathy complicating SARS-CoV-2 infection and Ad26.COV2.S vaccination: report of two cases
    Aggeliki Fotiadou
    Dimitrios Tsiptsios
    Stella Karatzetzou
    Sofia Kitmeridou
    Ioannis Iliopoulos
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 58
  • [37] Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines
    Pareek, Manan
    Sessa, Pasquale
    Polverino, Paolo
    Sessa, Francesco
    Kragholm, Kristian Hay
    Sessa, Maurizio
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [38] Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
    Sadoff, Jerald
    Le Gars, Mathieu
    Brandenburg, Boerries
    Cardenas, Vicky
    Shukarev, Georgi
    Vaissiere, Nathalie
    Heerwegh, Dirk
    Truyers, Carla
    de Groot, Anne Marit
    Jongeneelen, Mandy
    Kaszas, Krisztian
    Tolboom, Jeroen
    Scheper, Gert
    Hendriks, Jenny
    Ruiz-Guinazu, Javier
    Struyf, Frank
    Van Hoof, Johan
    Douoguih, Macaya
    Schuitemaker, Hanneke
    VACCINE, 2022, 40 (32) : 4403 - 4411
  • [39] Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
    Hung Nguyen, Van
    Boileau, Catherine
    Bogdanov, Alina
    Sredl, Meg
    Bonafede, Mac
    Ducruet, Thierry
    Chavers, Scott
    Rosen, Andrew
    Martin, David
    Buck, Philip
    Esposito, Daina
    van de Velde, Nicolas
    Mansi, James A.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (07):
  • [40] Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration
    Belda, Francisco
    Mora, Oscar
    Lopez-Martinez, Monica
    Torres, Nerea
    Vivanco, Ana
    Marfil, Silvia
    Pradenas, Edwards
    Massanella, Marta
    Blanco, Julia
    Christie, Rebecca
    Crowley, Michael
    PLASMATOLOGY, 2023, 17